CC#5: Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia Flashcards
Why is EIN clinically significant?
Precursor lesion to endometrial adenocarcinoma
Two-tiered classification system for endometrial hyperplasia
1) Hyperplasia w/o atypia (benign endometrial hyperplasia)
2) EIN-AEH
Essential histologic criteria for EIN-AEH (2)
Crowded glandular architecture, altered epithelial cytology distinct from surrounding endometrium and/or entrapped neoplastic glands
Desirable IHC criteria for EIN-AEH
Loss of immunoreactivity for PTEN/PAX2/MMR proteins
What does unopposed estrogenic stimulation lead to at level of endometrium?
Proliferative glandular epithelial changes/hyperplasia
Is benign hyperplasia a precursor to EIN-AEH/endometrial adenocarcinoma?
No, they are biologically distinct
What type of cancer is EIN-AEH a precursor lesion to?
Type I endometrial adenocarcinoma
Mortality risk among Black pts w/ endometrial cancer compared to White pts w/ endometrial cancer
55% higher 5-year mortality risk
One reason that Black individuals have higher mortality rate w/ endometrial cancer
More likely to be diagnosed w/ nonendometrioid (aggressive) histologies, though this alone does not account for mortality disparities
Difference between Asian/Pacific Islander pts compared to White pts regarding endometrial cancer presentation
Asian/Pacific Islanders more likely to present w/ advanced disease
What percentage of pts diagnosed with/ EIN-AEH who undergo hyst will have endometrial cancer in the hyst specimen?
~30-50%
What must be done if fertility-sparing tx is pursued for EIN-AEH?
Underlying/Occult endometrial cancer must be excluded via hysteroscopic uterine sampling
Primary objective in management of pt w/ EIN-AEH (2)
R/o endometrial cancer, design tx plan that can prevent/delay progression to endometrial cancer
Risk per year of EIN-AEH progressing to endometrial cancer
~8% per year
Advantages of hyst for tx of EIN-AEH (2)
Definitive assessment for poss concurrent carcinoma, effective tx of premalignant lesions that require no further therapy or f/u for EIN-AEH
Factors to consider when deciding on concomitant oophorectomy in premenopausal pts (2)
Risk of underlying endometrial cancer, risk of surgical menopause
Is supracervical hyst appropriate in tx of EIN-AEH, why or why not?
No, 2/2 inability to assess lowest extent of lesions (which may involve LUS/upper endocervix)
Intraop consideration when performing hyst for EIN-AEH
Intraop path assessment for occult carcinoma, as detection may require additional surgical management
How should morcellation be performed if EIN-AEH (if needed)?
Within contained environment (ie surgical bag) to prevent spillage
Downside of morcellation for EIN-AEH
Will likely make path interpretation more difficult
Is endometrial ablation appropriate tx for EIN-AEH?
No
Percentage of pts w/ EIN-AEH or grade 1 adenocarcinoma that demonstrated initial response to progestins; percentage of pts that demonstrated complete response (resolution) of EIN-AEH
86%; 66%
Overall rates of EIN-AEH disease regression shown w/ progestin therapy
50-90%
Routes of progesterone administration available (3)
PO, IU, combined
Is continuous PO progestin therapy more effective than cyclical therapy?
Yes
Adverse effect more likely w/ IU progestin methods; adverse effect more likely w/ PO progestin methods
VB; nausea
Recommended LNG-IUD device for management of EIN-AEH; delivery rate of this device
52-mg device; 20mcg/day
Progestational agent options for tx of EIN-AEH (4)
Megestrol acetate, medroxyprogesterone acetate, LNG-IUD, LNG-IUD + PO progestin
Which progestational tx method has higher regression rate?
LNG-IUD (though continuous PO progestins have been shown to be nearly as effective as LNG-IUD)
Regression rate seen w/ combined IU and PO progestins; regression rate seen w/ LNG-IUD alone
85%; 55%
Clinical benefits of LNG-IUD over PO progestins (3)
Lower rates of adverse events, higher rates of pt adherence, improved pt-reported health status scores (ie physical functioning, energy levels) over time
Recommended surveillance following total hyst w/o coexisting endometrial carcinoma
Not recommended, as surgery eliminates risk of disease progression
When is histologic reassessment recommended if EIN-AEH managed w/ progestational agents?
3-6 months
Poss outcomes seen on repeat endometrial sampling (4)
Resolution (complete response), regression, persistence, progression
Definition of resolution on repeat endometrial sampling
Atrophic/Secretory/ Proliferative endometrium w/o hyperplasia
Definition of regression on repeat endometrial sampling
Hyperplasia, but w/o atypia
Definition of persistence on repeat endometrial sampling
No change in histology at time of sampling
Definition of progression on repeat endometrial sampling
Cancer
Next step if no response or some regression during initial 3-6 months of progestin therapy
Consider additional 3-6 months of therapy
Next step if no response after 9-12 months of progestin therapy
Consider other management options (ie surgery)
Median time to complete resolution in pts w/ EIN-AEH managing w/ progestational agents
6 months (w/ range of 1 month to 18 months)
Factor associated w/ lack of response after 3 months of progestin tx
Failure to detect exogenous progesterone effect
Factor associated w/ nonresponse after 6 months of tx w/ LNG-IUD
Increased uterine diameter
Can repeat endometrial sampling be performed w/ IUD in place?
Yes
Method w/ some initial benefit demonstrated in predicting relapse after progestin therapy
Pre-tx hormone receptor expression (PR-A and PR-B) testing
Frequency/Duration for which repeat endometrial sampling should occur in pts using progestational agents
q3-6 months x2 years
Is recurrence rate of EIN-AEH elevated after initial response to progestational agents?
Yes
Recurrence rate for pts w/ EIN-AEH treated w/ progestational agents; median time to recurrence
~23%; 24 months
When can surveillance biopsies be discontinued in pts being treated w/ progestational agents?
After 2 years in pts w/o evidence of persistent/ recurrent/progressive disease and if asymptomatic w/o VB
When should therapy be continued long-term in pts being treated w/ progestational agents?
Pts who remain at risk for development of endometrial cancer
Risk factors for endometrial cancer (8)
Increasing age, late menopause, nulliparity, chronic anovulation, high-risk genetic conditions (ie Lynch syndrome, Cowden syndrome), use of unopposed estrogen therapy, obesity, T2DM
Risk of progression from EIN-AEH to carcinoma among pts receiving Megace tx through 4 years; cumulative risk of progression at 19 years after index bx
8.2%; 27.5%
Pregnancy rates among premenopausal pts w/ EIN-AEH managed w/ progestational agents
26-3-41.0%
Live-birth rate among EIN-AEH pts using ART; live-birth rate among EIN-AEH pts attempting spontaneous pregnancy
39.4%; 14.9%
Is IVF s/p fertility-sparing management of EIN-AEH or grade 1 endometrial adenocarcinoma associated w/ increased risk of recurrence?
No
Referral to consider in EIN-AEH pts interested in pregnancy
REI, as many pts also have conditions that can adversely affect fertility (ie PCOS, obesity, DM)
Percentage of endometrial cancer survivors who have obesity
> 75%
Lifestyle modification found to have positive effects on health outcomes, including endometrial cancer risk
Weight loss of 7-10% of TBW
Referral to consider for obese pts w/ endometrial hyperplasia
Bariatric surgery
Positive outcome associated w/ >10% weight loss from TBW
Such pts nearly 4x more likely to respond to LNG-IUD